Krystal Biotech Hits New 52-Week High of $382.26, Up 110% Yearly

Krystal Biotech, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 382.26 on June 30, 2026. This achievement underscores the company's strong performance over the past year, with a remarkable increase of 110.18%, significantly outpacing the S&P 500's growth of 20.86% during the same period. The company's market capitalization stands at USD 7,173 million, reflecting its position within the small-cap segment. Krystal Biotech's price-to-earnings (P/E) ratio is currently at 35.00, indicating investor expectations for future growth. Additionally, the company maintains a return on equity of 16.80%, showcasing its ability to generate profits from shareholders' equity. With a price-to-book ratio of 5.88 and a debt-to-equity ratio of -0.68, Krystal Biotech demonstrates a solid financial foundation. The stock's previous 52-week low was recorded at USD 130.50, highlighting the significant upward trajectory it has experienced. This new high marks an important moment for the company as it continues to navigate the competitive landscape of the biotechnology industry.